Ifimed Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Ifimed Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, gro…

2012-08-09 Mysuru, Karnataka Active Unlisted Active Compliant
Connect MCP
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Ifimed Pharmaceuticals Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
88/100
Trust Score
Low Risk

Ifimed Pharmaceuticals Private Limited is assessed as Low Risk with a Trust Score of 88/100. Ifimed Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 2012, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 16 Oct 2026 from the latest processed filings. Ifimed Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
88/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
75/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
85/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 85/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Moderate gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 3 open (3.71 cr) · 1 satisfied (60.00 Lakh).

Banking relationships (from registered charges)
LenderChargesAmount
Canara Bank1 48.0 cr
Others1 48.0 cr
Hdfc Bank Limited2 48.0 cr
Compliance Score: 75/100 Low Risk
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2024 - filings overdue.
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
PRABHUDEV PAVITHRA 01234567 Director 01/04/2018 6 yrs Approved
ANANTHARAMAIAH SUDEENDRA 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Key managerial personnel: ANANTHARAMAIAH SUDEENDRA (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
EPFO headcount growing - hiring signal.
Operating for 14+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Statutory filings appear overdue.
3 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence80/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment86/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 3 open charge(s) of 3.71 cr already registered.
  • Compliance record supports lending.
Investor view85/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 10 events
14 Oct 2025
Charge satisfied
Others
30 Sep 2024
Last AGM held
Annual general meeting
03 May 2024
Charge created
Canara Bank - 3.48 cr
31 Mar 2024
Latest balance sheet
Filed with ROC
15 Sep 2022
Charge created
Hdfc Bank Limited - 7.79 Lakh
31 Aug 2021
Charge created
Hdfc Bank Limited - 15.14 Lakh
09 Jun 2014
Charge created
Others - 60.00 Lakh
09 Aug 2012
Incorporated
Registered with Roc Bangalore
Director appointed
PRABHUDEV PAVITHRA (Director)
Director appointed
ANANTHARAMAIAH SUDEENDRA (Managing Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Mufaddel Timber And Allied Products Private Limited U20101KA1978PTC003363 Mysore, Karnataka
S N E Communication Private Limited U22100KA2020PTC132905 Mysore, Karnataka
Zariyaa Happy Wellbeing Private Limited U92100KA2016PTC086407 Mysore, Karnataka
Angoo Securities Consulting Private Limited U74999KA2009PTC128014 Mysore, Karnataka
Varkood Paper And Boards Private Limited U02101KA1995PTC018542 Mysore, Karnataka
Sri Sharada Properties Private Limited U70102KA2007PTC041681 Mysore, Karnataka
Bondplus Cement Products Private Limited U26999KA2021PTC143812 Mysore, Karnataka
Ksc Silks Private Limited U17200KA2021PTC148183 Mysore, Karnataka
Buildmight Developers (Opc) Private Limited U41001KA2024OPC195266 Mysore, Karnataka
Green Leaves Chits Private Limited U65992KA2011PTC059220 Mysore, Karnataka
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Ifimed Pharmaceuticals Private Limited before audits and certifications: compliance score 75/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Ifimed Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 85/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Ifimed Pharmaceuticals Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 88/100, distress signals and MSME payment-delay disclosures - know whether Ifimed Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Ifimed Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Ifimed Pharmaceuticals Private Limited an active company?

Ifimed Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 75/100 (Low Risk).

Is Ifimed Pharmaceuticals Private Limited financially healthy?

Ifimed Pharmaceuticals Private Limited has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Ifimed Pharmaceuticals Private Limited?

Its overall Trust Score is 88/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Ifimed Pharmaceuticals Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Ifimed Pharmaceuticals Private Limited have loans or charges against its assets?

3 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.

Is Ifimed Pharmaceuticals Private Limited up to date with its ROC filings?

Last balance sheet is for Mar 2024 - filings overdue. Overall compliance score: 75/100 (Low Risk).

Is it risky to lend to Ifimed Pharmaceuticals Private Limited?

Its Credit Risk Score is 85/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.